Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine Technology

January 23, 2024

https://www.prnewswire.com/news-releases/anixa-biosciences-announces-japanese-patent-on-ovarian-cancer-vaccine-technology-302041596.html

Broad coverage extended to Japan and related regions

SAN JOSE, Calif., Jan. 23, 2024 /PRNewswire/ — Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that its collaborator, Cleveland Clinic, has received a “Decision to Grant” notice from the Japan Patent Office (JPO) for the patent application titled “Ovarian Cancer Vaccines.”

Read more at prnewswire.com

Related news for (ANIX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.